KONKUK UNIVERSITY MEDICAL CENTER

Nine weeks of upfront treatment with the anticancer drug Leclaza can lower the stage of inoperable lung cancer patients with EGFR gene mutations, making them eligible for surgery. The study, presented at KATRD 2024, showed 55.8% partial remissions and 97.1% concordance in EGFR gene subtypes, with 77.3% sensitivity for stage I NSCLC diagnosis via lung lavage fluid biopsy.

A randomized, double-blind, placebo-controlled, non-inferiority trial in 3 Korean hospitals aims to compare ROTEM-guided TXA administration with preemptive TXA in elective cardiovascular surgery, focusing on postoperative blood loss, transfusions, and complications. The trial, registered in 2023, involves 764 patients and follows institutional protocols for perioperative management, with data managed by a CRO.